Exact Sciences Gets Compliance Warning Letter from Nasdaq | GenomeWeb

NEW YORK (GenomeWeb News) – Exact Sciences today said that the Nasdaq's listing qualifications staff sent the firm a letter last week informing it that its stock currently does not meet certain listing requirements.

Specifically, Nasdaq said that Exact is not in compliance with requirements that it maintain a minimum $35 million in market value of its listed securities, or stockholders' equity of at least $2.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.